A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs PF 5230907 (Primary)
  • Indications Cerebral haemorrhage
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Mar 2017 Results assessing the safety, pharmacokinetics and pharmacodynamics of PF-5230907 in healthy male volunteers, published in the Journal of Thrombosis and Haemostasis.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 01 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top